Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation

Open access

Abstract

The AML1 transcription factor is essential for normal hematopoiesis and is the target of several chromosomal translocations in acute leukemia. Acquired somatic AML1 mutations were recently demonstrated sporadically in de novo myelodysplasia (MDS) and acute myeloid leukemia (AML) including a few cases of therapy-related disease (t-MDS/t-AML). We examined 140 patients with t-MDS or t-AML for AML1 mutations by direct sequencing. We identified 9 missense, 3 nonsense, and 10 frameshift mutations, all heterozygous, in 22 patients (15.7%). Thirteen mutations were located in the N-terminal Runt homology domain (RHD), whereas 9 mutations were located in the C-terminal region including the transactivation domain (TAD). Nineteen patients with AML1 mutations had previously received alkylating agents whereas 2 patients had received radiotherapy only. AML1 mutations were highly significantly associated with presentation of the disease as t-MDS (P = .003), with deletion or loss of chromosome arm 7q (P = .001) and with subsequent transformation to overt t-AML (P = .0001). Patients with missense mutations presented a shorter survival compared with patients with nonsense/frameshift mutations (P = .03). Our results suggest that AML1 mutations and deletion of genes on chromosome arm 7q cooperate in leukemogenesis and predispose to leukemic transformation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2004-02-0754

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 135

Metadata

Authors
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J.
Affiliations
Rigshospitalet (DK)
Venue
Blood
Published
2004-09-01
Volume
104
Issue
5
Pages
1474-1481
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2154725061
Cited by
135
References
38
Citations by year
2025: 1 · 2023: 4 · 2022: 2 · 2021: 4 · 2020: 8 · 2019: 4 · 2018: 2 · 2017: 9 · 2016: 6 · 2015: 3 · 2014: 6 · 2013: 10 · 2012: 5
FWCI
5.66
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Funders
Kræftens Bekæmpelse
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Keywords
therapy-related myelodysplastic syndrome, therapy-related acute myeloid leukemia, alkylating agents, chromosome 7q deletion, leukemic transformation, transactivation domain, somatic mutations, leukemogenesis, survival
MeSH terms
Acute Disease, Adult, Aged, Cell Transformation, Neoplastic, Chromosome Deletion, Chromosomes, Human, Pair 7, DNA-Binding Proteins, Female, Humans, Leukemia, Myeloid, Male, Middle Aged, Proto-Oncogene Proteins, Transcription Factors, Frameshift Mutation, In Situ Hybridization, Fluorescence, Codon, Nonsense, Antineoplastic Agents, Alkylating, Loss of Heterozygosity, Mutation, Missense, Polymorphism, Single Nucleotide, Core Binding Factor Alpha 2 Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. https://app.cochat.ai/papers/10.1182/blood-2004-02-0754
The paper
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2004). Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood. https://doi.org/10.1182/blood-2004-02-0754

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.